Perrine Vuagnat
Villejuif, 94805, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
Atezolizumab and paclitaxel as first line therapy in advanced triple-negative breast cancer patients included in the French early access program.
Journal: Scientific reports
Published: March 12, 2023
Effectiveness of electronic patient reporting outcomes, by a digital telemonitoring platform, for prostate cancer care: the Protecty study.
Journal: Frontiers in digital health
Published: November 21, 2022
Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score.
Journal: Cancers
Published: July 20, 2022
Prognostic factors of toxicity of immune checkpoint inhibitors in nonsmall cell lung cancer and small cell lung cancer patients: The ToxImmune study.
Journal: Cancer reports (Hoboken, N.J.)
Published: July 17, 2022
Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers.
Journal: Journal for immunotherapy of cancer
Published: June 30, 2022
Predicting immunotherapy outcomes in patients with MSI tumors using NLR and CT global tumor volume.
Journal: Frontiers in oncology
Published: June 30, 2022
Oral Etoposide and Trastuzumab Use for HER2-Positive Metastatic Breast Cancer: A Retrospective Study from the Institut Curie Hospitals.
Journal: Cancers
Published: March 22, 2022
Effectiveness of a digital telemonitoring platform for cancer care of older patients: The ConnectElderlyPatientToDoctor study.
Journal: International journal of cancer
Published: March 11, 2022
PALLIA 10 score in phase I cancer studies.
Journal: BMJ supportive & palliative care
Published: February 28, 2022
Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers.
Journal: Journal of experimental & clinical cancer research : CR
Published: December 31, 2021
Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicities.
Journal: European journal of cancer (Oxford, England : 1990)
Published: May 24, 2021
Last Updated: 09/26/2026